TELA Bio, Inc.
NASDAQ:TELAMedical - Devices
+$0.09 today
- Market cap
- $51.00M
- Beta
- 1.36
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.72
Volume 0.22M
Average 0.17M
TELA Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
TELA Bio, Inc.NASDAQ: TELA
Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026
Change in working capital grows, but more slowly than its trailing trend
Q2 FY2026 change in working capital of $417K rose 13.6% year over year, behind the +144.9% change in trailing-twelve-month change in working capital.
Context
- Change in working capital amounted to 1.9% of revenue in FY2025, down 5.2 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +13.6% toward the trailing-twelve-month pace of +144.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 1.5M USD
- Year-over-year change
- +130.7%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.5M | +130.7% |
| FY2024 | 2024-12-31 | (4.87M) | -191.7% |
| FY2023 | 2023-12-31 | (1.67M) | +71.0% |
| FY2022 | 2022-12-31 | (5.76M) | -66.1% |
| FY2021 | 2021-12-31 | (3.47M) | — |
Change in Working Capital vs competitors
How TELA compares with its peers on the latest reported figures
- TELA's LTM Jun 2026 change in working capital of $884K is the 8th largest of the 9 companies compared; the peer median is $194.65K.
- Its year-over-year change of +144.9% is the 4th highest of 9, against a peer median of +117.2%.
- Change in working capital amounts to 1.1% of revenue for TELA, versus a peer median of 58.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.85M | +319.2% | — | 36.2% | |
| LTM Mar 2026 | $9.32M | +257.2% | — | 41.4% | |
| LTM Mar 2026 | $6.94M | +103.5% | — | 2082.3% | |
MDAISpectral AI, Inc. | LTM Mar 2026 | $3.37M | -7.7% | — | 20.2% |
| LTM Mar 2026 | $2.16M | -139.0% | — | — | |
| LTM Mar 2026 | $1.74M | -42.1% | +26.3% | 75.9% | |
| LTM Mar 2026 | $1.24M | +186.3% | +38.4% | 87.6% | |
| LTM Jun 2026 | $884K | +144.9% | — | 1.1% | |
| LTM Mar 2026 | $850K | +131.0% | — | — | |
| Peer median (excluding TELA) | $194.65K | +117.2% | +32.4% | 58.6% | |
Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.28M) | (44.3M) | (46.66M) | (37.84M) | (38.83M) |
| Depreciation & Amortization | 535K | 1.19M | 808K | 1.01M | 1.01M |
| Deferred Income Tax | 14K | 0 | 0 | (144K) | 230K |
| Stock-Based Compensation | 3.66M | 3.99M | 5.03M | 4.36M | 3.8M |
| Change in Working Capital | (3.47M) | (5.76M) | (1.67M) | (4.87M) | 1.5M |
| Accounts Receivables | (1.55M) | (2.42M) | (3.06M) | (762K) | (110K) |
| Inventory | (5.19M) | (6.07M) | (2.72M) | (2.97M) | (503K) |
| Accounts Payables | 1.6M | (884K) | 11K | 482K | 141K |
| Other Working Capital | 1.69M | 3.62M | 4.1M | (1.62M) | 1.97M |
| Other Non-Cash Items | 2.1M | 4.14M | 1.64M | (4.12M) | 4.08M |
| Operating Cash Flow | (30.43M) | (40.75M) | (40.86M) | (41.6M) | (28.22M) |
| Capital Expenditures | (627K) | (1.87M) | (611K) | (989K) | (448K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1.29M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (1M) | 12K | 5.44M | 0 |
| Investing Cash Flow | (627K) | (1.87M) | (599K) | 4.45M | 846K |
| Debt Repayment | 0 | 10M | 0 | 0 | 14.03M |
| Common Stock Issued | 585K | 34.4M | 46.34M | 42.92M | 11.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 105K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.55M) | (74K) | 138K | (205K) |
| Financing Cash Flow | 585K | 40.85M | 46.27M | 43.06M | 25.75M |
| Effect of Forex Changes | 11K | (144K) | 164K | 28K | (217K) |
| Net Change in Cash | (30.46M) | (1.91M) | 4.98M | 5.94M | (1.84M) |
| Free Cash Flow | (31.06M) | (42.62M) | (41.47M) | (42.58M) | (28.67M) |
TELA Bio, Inc.
NASDAQ:TELA
Intrinsic Alpha fair value
Locked
Current Price
$1.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.